TY  - JOUR
AU  - Hoberger, Michael
AU  - Zuber, Romy L
AU  - Burkhard-Meier, Anton
AU  - Di Gioia, Dorit
AU  - Jurinovic, Vindi
AU  - Völkl, Michael
AU  - Güler, Sinan E
AU  - Albertsmeier, Markus
AU  - Klein, Alexander
AU  - Dürr, Hans Roland
AU  - Schmidt-Hegemann, Nina-Sophie
AU  - Knösel, Thomas
AU  - Kunz, Wolfgang G
AU  - von Bergwelt-Baildon, Michael
AU  - Lindner, Lars H
AU  - Berclaz, Luc M
TI  - Long-term benefit from high-dose ifosfamide in sarcoma depends on sustained prior control and timely intervention: a machine learning analysis.
JO  - Journal of cancer research and clinical oncology
VL  - 152
IS  - 1
SN  - 0301-1585
CY  - Heidelberg
PB  - Springer
M1  - DKFZ-2026-00074
SP  - 34
PY  - 2026
N1  - #DKTKZFB9#
AB  - High-dose ifosfamide (HD-IFO) remains an effective regimen for advanced bone and soft tissue sarcomas, but predictors of long-term benefit are poorly defined. This study evaluated clinical outcomes and prognostic factors using machine learning-assisted modeling in sarcoma patients treated with HD-IFO at a high-volume academic center.We retrospectively analyzed 26 patients with histologically confirmed bone or soft tissue sarcoma who received HD-IFO (≥ 12 g/m2 per cycle) between 2015 and 2025. Progression-free survival (PFS) and overall survival (OS) were estimated by the Kaplan-Meier method and compared across RECIST response categories using log-rank testing. Prognostic factors were identified using Least Absolute Shrinkage and Selection Operator (LASSO) logistic regression with leave-one-out cross-validation. The top three variables were entered into multivariable logistic regression to estimate odds ratios (ORs) for OS > 24 months.Median PFS and OS from start of HD-IFO was 6.6 months (95
KW  - Humans
KW  - Ifosfamide: administration & dosage
KW  - Ifosfamide: therapeutic use
KW  - Female
KW  - Male
KW  - Machine Learning
KW  - Middle Aged
KW  - Retrospective Studies
KW  - Sarcoma: drug therapy
KW  - Sarcoma: pathology
KW  - Sarcoma: mortality
KW  - Adult
KW  - Antineoplastic Agents, Alkylating: administration & dosage
KW  - Antineoplastic Agents, Alkylating: therapeutic use
KW  - Aged
KW  - Young Adult
KW  - Prognosis
KW  - Bone Neoplasms: drug therapy
KW  - Bone Neoplasms: pathology
KW  - Bone Neoplasms: mortality
KW  - Adolescent
KW  - Bone sarcoma (Other)
KW  - High-dose ifosfamide (Other)
KW  - Machine learning-assisted modeling (Other)
KW  - Soft tissue sarcoma (Other)
KW  - Ifosfamide (NLM Chemicals)
KW  - Antineoplastic Agents, Alkylating (NLM Chemicals)
LB  - PUB:(DE-HGF)16
C6  - pmid:41504936
DO  - DOI:10.1007/s00432-025-06410-8
UR  - https://inrepo02.dkfz.de/record/307579
ER  -